Kostas Biliouris
Stock Analyst at BMO Capital
(0.87)
# 3,793
Out of 4,905 analysts
59
Total ratings
29.17%
Success rate
-21.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $3.33 | +20.12% | 1 | Jul 8, 2025 | |
| VERV Verve Therapeutics | Downgrades: Market Perform | $20 → $14 | $10.91 | +23.74% | 3 | Jun 27, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $300 → $360 | $320.53 | +12.31% | 5 | Jun 24, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $120 → $70 | $14.08 | +397.34% | 5 | Jun 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.04 | +163.16% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $33.76 | +113.27% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $9.02 | +454.32% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.95 | +320.17% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $41.75 | +7.78% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $12.06 | +314.59% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.61 | +637.53% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $15.69 | +123.07% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.99 | +754.27% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $4.22 | +847.87% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $41.59 | +116.40% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $13.50 | +788.89% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $20.75 | +174.70% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $46.51 | -20.45% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $57.29 | +74.55% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $4.13 | +360.05% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $65.13 | +50.47% | 1 | Jun 17, 2022 |
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $3.33
Upside: +20.12%
Verve Therapeutics
Jun 27, 2025
Downgrades: Market Perform
Price Target: $20 → $14
Current: $10.91
Upside: +23.74%
Alnylam Pharmaceuticals
Jun 24, 2025
Maintains: Outperform
Price Target: $300 → $360
Current: $320.53
Upside: +12.31%
Sarepta Therapeutics
Jun 16, 2025
Downgrades: Market Perform
Price Target: $120 → $70
Current: $14.08
Upside: +397.34%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.04
Upside: +163.16%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $33.76
Upside: +113.27%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $9.02
Upside: +454.32%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.95
Upside: +320.17%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $41.75
Upside: +7.78%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $12.06
Upside: +314.59%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.61
Upside: +637.53%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $15.69
Upside: +123.07%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.99
Upside: +754.27%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $4.22
Upside: +847.87%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $41.59
Upside: +116.40%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $13.50
Upside: +788.89%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $20.75
Upside: +174.70%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $46.51
Upside: -20.45%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $57.29
Upside: +74.55%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $4.13
Upside: +360.05%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $65.13
Upside: +50.47%